These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

253 related articles for article (PubMed ID: 27815262)

  • 1. p53-/- synergizes with enhanced NrasG12D signaling to transform megakaryocyte-erythroid progenitors in acute myeloid leukemia.
    Zhang J; Kong G; Rajagopalan A; Lu L; Song J; Hussaini M; Zhang X; Ranheim EA; Liu Y; Wang J; Gao X; Chang YI; Johnson KD; Zhou Y; Yang D; Bhatnagar B; Lucas DM; Bresnick EH; Zhong X; Padron E; Zhang J
    Blood; 2017 Jan; 129(3):358-370. PubMed ID: 27815262
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A gain-of-function p53 mutant synergizes with oncogenic NRAS to promote acute myeloid leukemia in mice.
    Rajagopalan A; Feng Y; Gayatri MB; Ranheim EA; Klungness T; Matson DR; Lee MH; Jung MM; Zhou Y; Gao X; Nadiminti KV; Yang DT; Tran VL; Padron E; Miyamoto S; Bresnick EH; Zhang J
    J Clin Invest; 2023 Dec; 133(24):. PubMed ID: 37847561
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Asxl1 loss cooperates with oncogenic Nras in mice to reprogram the immune microenvironment and drive leukemic transformation.
    You X; Liu F; Binder M; Vedder A; Lasho T; Wen Z; Gao X; Flietner E; Rajagopalan A; Zhou Y; Finke C; Mangaonkar A; Liao R; Kong G; Ranheim EA; Droin N; Hunter AM; Nikolaev S; Balasis M; Abdel-Wahab O; Levine RL; Will B; Nadiminti KVG; Yang D; Geissler K; Solary E; Xu W; Padron E; Patnaik MM; Zhang J
    Blood; 2022 Feb; 139(7):1066-1079. PubMed ID: 34699595
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Ras oncogene-independent activation of RALB signaling is a targetable mechanism of escape from NRAS(V12) oncogene addiction in acute myeloid leukemia.
    Pomeroy EJ; Lee LA; Lee RDW; Schirm DK; Temiz NA; Ma J; Gruber TA; Diaz-Flores E; Moriarity BS; Downing JR; Shannon KM; Largaespada DA; Eckfeldt CE
    Oncogene; 2017 Jun; 36(23):3263-3273. PubMed ID: 27991934
    [TBL] [Abstract][Full Text] [Related]  

  • 5. PRDM16s transforms megakaryocyte-erythroid progenitors into myeloid leukemia-initiating cells.
    Hu T; Morita K; Hill MC; Jiang Y; Kitano A; Saito Y; Wang F; Mao X; Hoegenauer KA; Morishita K; Martin JF; Futreal PA; Takahashi K; Nakada D
    Blood; 2019 Aug; 134(7):614-625. PubMed ID: 31270104
    [TBL] [Abstract][Full Text] [Related]  

  • 6. NrasG12D oncoprotein inhibits apoptosis of preleukemic cells expressing Cbfβ-SMMHC via activation of MEK/ERK axis.
    Xue L; Pulikkan JA; Valk PJ; Castilla LH
    Blood; 2014 Jul; 124(3):426-36. PubMed ID: 24894773
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Oncogenic NRAS Primes Primary Acute Myeloid Leukemia Cells for Differentiation.
    Brendel C; Teichler S; Millahn A; Stiewe T; Krause M; Stabla K; Ross P; Huynh M; Illmer T; Mernberger M; Barckhausen C; Neubauer A
    PLoS One; 2015; 10(4):e0123181. PubMed ID: 25901794
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Endogenous oncogenic Nras mutation initiates hematopoietic malignancies in a dose- and cell type-dependent manner.
    Wang J; Liu Y; Li Z; Wang Z; Tan LX; Ryu MJ; Meline B; Du J; Young KH; Ranheim E; Chang Q; Zhang J
    Blood; 2011 Jul; 118(2):368-79. PubMed ID: 21586752
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Dominant role of oncogene dosage and absence of tumor suppressor activity in Nras-driven hematopoietic transformation.
    Xu J; Haigis KM; Firestone AJ; McNerney ME; Li Q; Davis E; Chen SC; Nakitandwe J; Downing J; Jacks T; Le Beau MM; Shannon K
    Cancer Discov; 2013 Sep; 3(9):993-1001. PubMed ID: 23733505
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Nras(G12D/+) promotes leukemogenesis by aberrantly regulating hematopoietic stem cell functions.
    Wang J; Kong G; Liu Y; Du J; Chang YI; Tey SR; Zhang X; Ranheim EA; Saba-El-Leil MK; Meloche S; Damnernsawad A; Zhang J; Zhang J
    Blood; 2013 Jun; 121(26):5203-7. PubMed ID: 23687087
    [TBL] [Abstract][Full Text] [Related]  

  • 11. NRASG12V oncogene facilitates self-renewal in a murine model of acute myelogenous leukemia.
    Sachs Z; LaRue RS; Nguyen HT; Sachs K; Noble KE; Mohd Hassan NA; Diaz-Flores E; Rathe SK; Sarver AL; Bendall SC; Ha NA; Diers MD; Nolan GP; Shannon KM; Largaespada DA
    Blood; 2014 Nov; 124(22):3274-83. PubMed ID: 25316678
    [TBL] [Abstract][Full Text] [Related]  

  • 12. NRAS mutations in de novo acute leukemia: prevalence and clinical significance.
    Dunna NR; Vuree S; Anuradha C; Sailaja K; Surekha D; Digumarti RR; Rao VR; Yadav SK; Reddy R; Vishnupriya S
    Indian J Biochem Biophys; 2014 Jun; 51(3):207-10. PubMed ID: 25204082
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Preclinical efficacy of MEK inhibition in Nras-mutant AML.
    Burgess MR; Hwang E; Firestone AJ; Huang T; Xu J; Zuber J; Bohin N; Wen T; Kogan SC; Haigis KM; Sampath D; Lowe S; Shannon K; Li Q
    Blood; 2014 Dec; 124(26):3947-55. PubMed ID: 25361812
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Loss of Dnmt3a and endogenous Kras(G12D/+) cooperate to regulate hematopoietic stem and progenitor cell functions in leukemogenesis.
    Chang YI; You X; Kong G; Ranheim EA; Wang J; Du J; Liu Y; Zhou Y; Ryu MJ; Zhang J
    Leukemia; 2015 Sep; 29(9):1847-56. PubMed ID: 25801914
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Overexpression of sPRDM16 coupled with loss of p53 induces myeloid leukemias in mice.
    Shing DC; Trubia M; Marchesi F; Radaelli E; Belloni E; Tapinassi C; Scanziani E; Mecucci C; Crescenzi B; Lahortiga I; Odero MD; Zardo G; Gruszka A; Minucci S; Di Fiore PP; Pelicci PG
    J Clin Invest; 2007 Dec; 117(12):3696-707. PubMed ID: 18037989
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Hematopoiesis and leukemogenesis in mice expressing oncogenic NrasG12D from the endogenous locus.
    Li Q; Haigis KM; McDaniel A; Harding-Theobald E; Kogan SC; Akagi K; Wong JC; Braun BS; Wolff L; Jacks T; Shannon K
    Blood; 2011 Feb; 117(6):2022-32. PubMed ID: 21163920
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Anti-leukemic effects of simvastatin on NRAS
    Jang J; Lee J; Jang JH; Jung CW; Park S
    Mol Biol Rep; 2019 Dec; 46(6):5859-5866. PubMed ID: 31452046
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cooperation of Dnmt3a R878H with Nras G12D promotes leukemogenesis in knock-in mice: a pilot study.
    Shi X; Yang Y; Shang S; Wu S; Zhang W; Peng L; Huang T; Zhang R; Ren R; Mi J; Wang Y
    BMC Cancer; 2019 Nov; 19(1):1072. PubMed ID: 31703632
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cooperative Epigenetic Remodeling by TET2 Loss and NRAS Mutation Drives Myeloid Transformation and MEK Inhibitor Sensitivity.
    Kunimoto H; Meydan C; Nazir A; Whitfield J; Shank K; Rapaport F; Maher R; Pronier E; Meyer SC; Garrett-Bakelman FE; Tallman M; Melnick A; Levine RL; Shih AH
    Cancer Cell; 2018 Jan; 33(1):44-59.e8. PubMed ID: 29275866
    [TBL] [Abstract][Full Text] [Related]  

  • 20. First SAR Study for Overriding NRAS Mutant Driven Acute Myeloid Leukemia.
    Cho H; Shin I; Ju E; Choi S; Hur W; Kim H; Hong E; Kim ND; Choi HG; Gray NS; Sim T
    J Med Chem; 2018 Sep; 61(18):8353-8373. PubMed ID: 30153003
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.